ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

KZIA Kazia Therapeutics Ltd

0.2805
0.0205 (7.88%)
Pre Market
Last Updated: 04:35:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 250
Bid Price 0.2031
Ask Price 0.2804
News -
Share Name Share Symbol Market Stock Type
Kazia Therapeutics Ltd KZIA NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.0205 7.88% 0.2805 04:35:01
Open Price Low Price High Price Close Price Previous Close
0.26
Trades Shares Traded Average Volume
1 250 -
Last Trade Type Quantity Price Currency
04:35:01 formt 250  0.2805 USD

Kazia Therapeutics Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 228.03M - 0 -20.47M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Kazia Therapeutics

Date Time Source Heading
5/29/202407:55Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign..
5/23/202413:41PR Newswire (US)Kazia Granted 180-Day Extension by Nasdaq to Meet the..
5/23/202406:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
5/23/202406:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
5/17/202415:07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
5/17/202415:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
5/01/202407:45PR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801..
3/21/202407:52PR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for..
3/13/202407:00PR Newswire (US)Kazia announces presentation of new data at AACR Annual..
2/21/202415:19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
2/21/202408:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/21/202406:30PR Newswire (US)Kazia Therapeutics Reports Early Conclusion of Clinical..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KZIA Message Board. Create One! See More Posts on KZIA Message Board See More Message Board Posts

KZIA Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others.